当前位置: X-MOL 学术Drug Resist. Updat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Drug Resistance Updates ( IF 24.3 ) Pub Date : 2017-07-24 , DOI: 10.1016/j.drup.2017.07.001
Stefano Coppola , Ilaria Carnevale , Erik H.J. Danen , Godefridus J. Peters , Thomas Schmidt , Yehuda G. Assaraf , Elisa Giovannetti

Pancreatic ductal adenocarcinoma (PDAC) is a highly chemoresistant malignancy. This chemoresistant phenotype has been historically associated with genetic factors. Major biomedical research efforts were concentrated that resulted in the identification of subtypes characterized by specific genetic lesions and gene expression signatures that suggest important biological differences. However, to date, these distinct differences could not be exploited for therapeutic interventions. Apart from these genetic factors, desmoplasia and tumor microenvironment have been recognized as key contributors to PDAC chemoresistance. However, while several strategies targeting tumor-stroma have been explored including drugs against members of the Hedgehog family, they failed to meet the expectations in the clinical setting. These unsatisfactory clinical results suggest that, an important link between genetics and the influence of tumor microenvironment on PDAC chemoresistance remains to be elucidated. In this respect, mechanobiology is an emerging multidisciplinary field that encompasses cell and developmental biology as well as biophysics and bioengineering. Herein we provide a comprehensive overview of the key players in pancreatic cancer chemoresistance from the perspective of mechanobiology, and discuss novel experimental avenues such as elastic micropillar arrays that could provide fresh insights for the development of mechanobiology-targeted therapeutic approaches (know as mechanopharmacology) to overcome anticancer drug resistance in pancreatic cancer.



中文翻译:

克服胰腺癌化学耐药性的机械药理学方法

胰腺导管腺癌(PDAC)是高度化学耐药的恶性肿瘤。历史上,这种化学抗性表型与遗传因素有关。集中了主要的生物医学研究成果,从而鉴定了以特定的遗传性病变和基因表达特征为特征的亚型,这些亚型表明了重要的生物学差异。然而,迄今为止,这些明显的差异还不能用于治疗干预。除这些遗传因素外,增生和肿瘤微环境也被认为是PDAC化学耐药性的关键因素。然而,尽管已经探索了几种针对肿瘤基质的策略,包括针对刺猬家族成员的药物,但它们未能满足临床要求。这些不令人满意的临床结果表明,遗传学和肿瘤微环境对PDAC化学耐药性的影响之间的重要联系仍有待阐明。在这方面,机械生物学是一个新兴的多学科领域,涵盖细胞和发育生物学以及生物物理学和生物工程学。在这里,我们从力学生物学的角度全面概述了胰腺癌化学抵抗的关键因素,并讨论了诸如弹性微柱阵列等新颖的实验方法,这些新方法可以为以生物学为目标的治疗方法(称为机械药理学)的发展提供新的见解。克服胰腺癌的抗癌药耐药性。遗传学与肿瘤微环境对PDAC化学耐药性的影响之间的重要联系仍有待阐明。在这方面,机械生物学是一个新兴的多学科领域,涵盖细胞和发育生物学以及生物物理学和生物工程学。在这里,我们从力学生物学的角度全面概述了胰腺癌化学抵抗的关键因素,并讨论了诸如弹性微柱阵列等新颖的实验方法,这些新方法可以为以生物学为目标的治疗方法(称为机械药理学)的发展提供新的见解。克服胰腺癌的抗癌药耐药性。遗传学与肿瘤微环境对PDAC化学耐药性的影响之间的重要联系仍有待阐明。在这方面,机械生物学是一个新兴的多学科领域,涵盖细胞和发育生物学以及生物物理学和生物工程学。在这里,我们从力学生物学的角度全面概述了胰腺癌化学抵抗的关键因素,并讨论了诸如弹性微柱阵列之类的新颖实验方法,这些新方法可以为以生物学为目标的治疗方法(称为机械药理学)的发展提供新的见解。克服胰腺癌的抗癌药耐药性。机械生物学是一个新兴的多学科领域,涵盖细胞和发育生物学以及生物物理学和生物工程学。在这里,我们从力学生物学的角度全面概述了胰腺癌化学抵抗的关键因素,并讨论了诸如弹性微柱阵列等新颖的实验方法,这些新方法可以为以生物学为目标的治疗方法(称为机械药理学)的发展提供新的见解。克服胰腺癌的抗癌药耐药性。机械生物学是一个新兴的多学科领域,涵盖细胞和发育生物学以及生物物理学和生物工程学。在这里,我们从力学生物学的角度全面概述了胰腺癌化学抵抗的关键因素,并讨论了诸如弹性微柱阵列等新颖的实验方法,这些新方法可以为以生物学为目标的治疗方法(称为机械药理学)的发展提供新的见解。克服胰腺癌的抗癌药耐药性。

更新日期:2017-07-24
down
wechat
bug